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To the Editor:
Approximately 20,000 cardiac transplant recipients currently reside in the United States. Rejection
remains a major cause of graft failure and requires lifelong surveillance. The current gold standard for 
monitoring rejection is catheter-based endomyocardial biopsy (EMB), which is associated with risk
and expense (1). Donor-specific cell-free deoxyribonucleic acid (DScf-DNA) has been proposed as a
marker for cellular injury caused by rejection (2). Shotgun whole-genome sequencing (WGS) has been
used to detect DScf-DNA (3). The complexity and cost of the analysis required by WGS limits its
application as a surveillance tool. We have employed targeted quantitative genotyping to determine the
%DScf-DNA. The targeted approach relies on selected highly-informative genomic regions and
potentially provides a rapid (24 to 48 h) cost-efficient (significantly less than whole genome sequencing)
method suitable for clinical surveillance. We applied this method to detect DScf-DNA in pediatric cardiac
transplant recipients in a prospective blinded study.
Cardiac transplant recipients followed at the Herma Heart Center at the Children’s Hospital of Wisconsin
were invited to participate. Blood samples (5 ml) were collected in 3 clinical scenarios:
1. Scheduled surveillance EMB from asymptomatic heart transplant recipients in
the catheterization laboratory immediately before scheduled surveillance EMB.
2. Unscheduled diagnostic EMB from symptomatic heart transplant recipients before
unscheduled diagnostic EMB.
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3. Rejection from heart transplant recipients with biopsy- proven rejection (> The International
Society for Heart and Lung Transplantation grade 2R or antibody mediated rejection 1) before 
initiation of treatment, during treatment, and at 1 week.
Clinical, laboratory, cardiac catheterization, and echocardiographic data were recorded. Anticoagulated
blood was collected to measure cell-free deoxyribonucleic acid (cf-DNA) levels. Plasma separation, cf-
DNA extraction, and quantification of total cf-DNA were carried out as previously described (4). Genomic
DNA for genotyping was prepared from 1 buffy coat of each recipient, and donor DNA was obtained
from the Blood Center of Wisconsin. Determination of the %DScf-DNA in recipient plasma was
performed using Digital Analysis of Selected Regions (DANSR, Ariosa Diagnostics, San Jose,
California) (5). Genotyping of donor and recipient genomic DNA was carried out by the same assay. Loci 
are informative when recipient genotypes are homozygous and donor genotypes are either 
heterozygous or homozygous for the other allele. The minor allele frequency for informative loci was
modeled as a binomial distribution. The %DScf-DNA was defined as the peak from this modeling.
Summary statistics included median and range. Unpaired samples (i.e., rejection group vs. surveillance
group) were compared using a Mann-Whitney U test. Rejection samples were compared with a
Friedman analysis of variance. A Pearson correlation summarized correlations. A p value <0.05 was
considered significant.
Fifty-three samples from 32 patients were analyzed.
Scenario 1
The cf-DNA levels were obtained from 26 patients undergoing 38 scheduled surveillance EMBs (Fig. 1A). 
Thirty-two (84%) samples contained <1% DScf-DNA. No patient with DScf-DNA <1% had pathological 
rejection. DScf-DNA levels exceeded 1% in 6 samples, and the highest percentage of DScf-DNA was
associated with asymptomatic biopsy-proven rejection. The remaining 5 samples had negative biopsies.
Figure 1. cf-DNA in Patients Undergoing Surveillance EMB and During Rejection
Percent donor-specific cell-free deoxyribonucleic acid (DScf-DNA) in scheduled
surveillance endomyocardial biopsy (EMB) (A) and unscheduled diagnostic EMB samples (B). (C) Boxplot 
     
   
       
      
       
  
 
     
     
    
     
  
    
    
 
 
 
     
  
   
    
     
   
 
     
   
   
  
     
    
     
  
     
      
     
  
  
  
of surveillance EMB samples (black circles) and rejection samples (red circles) collected at 3 time
points. (D)Total cell-free deoxyribonucleic acid (cf-DNA) in unscheduled diagnostic EMB samples. Data
in A, B, and D are sorted on the x-axis according to increasing %DScf-DNA. Samples in B and D align
vertically. The dashed line in A, B, and C highlights the 1% DScf-DNA level. The vertical solid line in
A orients the picture so that all samples containing <1% DScf-DNA are on the left-hand side and all 
samples >1% are on the right. IV = intravenous.
Scenario 2
Seven samples were obtained from 6 patients before unscheduled diagnostic EMB to rule out rejection
based on clinical criteria (Figs. 1B and 1D). Six samples had DScf-DNA levels >1%, and 1 sample contained
DScf-DNA <1%. Four of the 6 were associated with biopsy-proven rejection; the other 2 patients had
significant coronary arteryvasculopathy on angiography. The single symptomatic patient with a low
percentage of DScf-DNA had high levels of total cf-DNA (Fig. 1D), implying that the dominant pathology
was global rather than confined to the donor organ. This patient was diagnosed with culture-
positive sepsis, the accompanying EMB was negative for rejection, and coronary angiography was
normal.
Scenario 3
Four patients with biopsy-proven rejection were analyzed. All pre-treatment samples collected at 
diagnosis contained DScf-DNA >1% (sensitivity 100%). Following intravenous immunosuppressive
therapy, all patients demonstrated significantly decreased %DScf-DNA. Interestingly, 3 to 4 days after 
discontinuing augmented immunosuppression, the %DScf-DNA rebounded in 3 of 4 patients (Fig. 1C). 
The DScf-DNA was compared with other candidate noninvasive laboratory variables (B-natriuretic
peptide, troponin, and C-reactive protein) as well as echocardiographically determined left ventricular
ejection fraction in predicting rejection on biopsy; DScf-DNA had the highest sensitivity and specificity
(100% and 84%, respectively).
DScf-DNA may be sufficiently sensitive to detect rejection and injury to the donor organ earlier than
currently available methods. Levels of DScf-DNA fall consistently by 1 week post-transplant, which may
allow for noninvasive detection of rejection in the vulnerable early post-transplant period (data not
shown). A sensitive noninvasive rejection monitoring method could decrease the number of biopsies
needed over a lifespan, thereby considerably decreasing complications, discomfort, and cost. We were
able to detect all rejection episodes, including both cellular and antibody-mediated rejection, at the 
earliest onset and even before clinical indicators of disease. However, these results are based on a
limited sample size. A larger validation study is needed.
In summary, targeted quantitative genotyping was employed to determine circulating levels of DScf-
DNA in pediatric heart transplant recipients. The percentage of DScf-DNA was elevated in all patients
diagnosed with rejection. Further, all patients with DScf-DNA levels <1% were shown by biopsy and
clinical parameters to be negative for rejection (negative predictive value 100%). Targeted quantitative 
genotyping of circulating DScf-DNA constitutes a sensitive, rapid, and cost-effective noninvasive tool 
potentially suitable for rejection surveillance as an alternative to EMB.
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